@article {BarulliP01.109作者={玛丽亚蔷薇花坛Barulli和玛丽安娜Tursi Rosanna Tortelli和罗莎Capozzo罗赞娜Cortese Eustachio D {\ textquoteright} Errico和安东尼奥·利奥和伊莎贝拉西蒙和吉安卡洛Logroscino}, title = {ALS患者的语言学习能力(P01.109)},体积={78}={1}补充数量,页面= {P01.109——P01.109} ={2012},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:研究ALS的神经认知障碍谱系。首页背景神经认知障碍主要包括执行功能障碍(1)。另一方面,不清楚内存是主要涉及(2).Design /方法:连续55 ALS患者运动NeuronCenter,巴里大学神经学系。首页诊断是基于El堆渣场标准(布鲁克斯,1994)。招募了七十名健康与控制。我们检查了记忆能力通过雷伊{\ textquoteright}年代听觉言语学习测试(RAVLT):自由回忆在五个试验,直接和延迟回忆,语言学习,语言遗忘小学和近因效应的分数。所有受试者完成下面的神经心理学电池:迷你精神状态检查(MMSE)、额评估电池(FAB):数字广度向前(DSF);数字广度向后(双边带);注意力矩阵(点);言语流畅性测试(音频电报);Stroop测试(ST);乌鸦{\ textquoteright}年代彩色矩阵(RCM)。Results: we enrolled 33 men and 22 women in ALS group (age 59.7{\textpm}9.7; educational level 9.6{\textpm}4.1 yrs; disease duration at baseline 30.9{\textpm}32.1 months; ALSFRS-r 37.8{\textpm}6.2; FVC 92.5{\textpm}22.7; MMT 8.1{\textpm}1.3). Compared with controls, ALS patients performed worse on the recall immediate (p=.007). The recency and primary effect was less evident in ALS than control group (p=.018; p=.004). Moreover, the ALS group performed worse on short-term memory (DSF, p=.005), working memory (DSB, p=.000), verbal fluency (VFT, p=.000), flexibility (RCM, p=.025) and general cognitive abilities (MMSE, p=.001; FAB, p=.009). The different indices of RAVLT showed a significant correlation with all executive measures in ALS group.Conclusions: ALS patients present impairment of both executive and memory dysfunctions. The executive dysfunctions are primary involved with failure of elaborative encoding and strategic retrieval processing, as a consequence of verbal learning identified by free recall, recency and primary effect scores. On the other hand, storage processes, a main component of memory, are intact.Disclosure: Dr. Barulli has nothing to disclose. Dr. Tursi has nothing to disclose. Dr. Barulli has nothing to disclose. Dr. Capozzo has nothing to disclose. Dr. Barulli has nothing to disclose. Dr. D{\textquoteright}Errico has nothing to disclose. Dr. Leo has nothing to disclose. Dr. Simone has received personal compensation for activities with Sanofi-Aventis and Biogen Idec. Dr. Logroscino has received personal compensation for activities with Novartis, Glaxo and Boerhinger.Monday, April 23 2012, 14:00 pm-18:30 pm}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/78/1_Supplement/P01.109}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }